Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2015-01-21085,2015,Kim 2015 Ann Intern Med,1.3e+006,"Cytologic test every year VERSUS Cytologic testing every 3 years, cotesting at age >=30 years old every 5 years IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.",26414147,"Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- United States.",Cytologic test every year,Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.,"Cytologic testing every 3 years, cotesting at age >=30 years old every 5 years",NE
2015-01-21085,2015,Kim 2015 Ann Intern Med,17000,"Cytologic testing every 3 years VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.",26414147,"Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.",Cytologic testing every 3 years,Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.,None,NE
2015-01-21085,2015,Kim 2015 Ann Intern Med,22000,"Current Screening practice VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.",26414147,"Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.",Current Screening practice,Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.,None,NE
2015-01-21085,2015,Kim 2015 Ann Intern Med,67000,"Cytologic testing every 3 years, cotesting at age >=30 years old every 5 years VERSUS Cytologic testing every 3 years IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.",26414147,"Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- United States.","Cytologic testing every 3 years, cotesting at age >=30 years old every 5 years",Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.,Cytologic testing every 3 years,NE
2014-01-16271,2014,Ryabov 2014 Public Health,17000,"Monthly visits from community health workers (CHW's) providing well-structured educational message, self management
plan VERSUS no monthly visits from CHW's IN Specific disease- type-2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Mexico.",24999158,Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Mexico.,"Monthly visits from community health workers (CHW's) providing well-structured educational message, self management plan",Cost-effectiveness of Community Health Workers in controlling diabetes epidemic on the U.S.-Mexico border.,no monthly visits from CHW's,NE
2014-01-15548,2014,Home 2014 J Med Econ,17000,Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- South Korea; Other- insulin-naÃ¯ve.,25407031,Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- South Korea; Other- insulin-naÃ¯ve.,Insulin detemir,An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.,oral glucose-lowering drugs (OGLDs),NE
2014-01-15548,2014,Home 2014 J Med Econ,4.4e+006,Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- Indonesia; Other- insulin-naÃ¯ve.,25407031,Specific disease- type 2 diabetes; Age- 41 to 64 years; Gender- Both; Country- South Korea; Other- insulin-naÃ¯ve.,Insulin detemir,An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.,oral glucose-lowering drugs (OGLDs),NE
2014-01-15548,2014,Home 2014 J Med Econ,410000,"Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Algeria; Other- insulin-naÃ¯ve.",25407031,"Specific disease- type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Algeria; Other- insulin-naÃ¯ve.",Insulin detemir,An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.,oral glucose-lowering drugs (OGLDs),NE
2014-01-15548,2014,Home 2014 J Med Econ,44000,"Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- India; Other- insulin-naÃ¯ve.",25407031,"Specific disease- type 2 diabetes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- India; Other- insulin-naÃ¯ve.",Insulin detemir,An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.,oral glucose-lowering drugs (OGLDs),NE
2014-01-15548,2014,Home 2014 J Med Econ,Cost-Saving,"Insulin detemir VERSUS oral glucose-lowering drugs (OGLDs) IN Specific disease- type 2 diabetes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Mexico; Other- insulin-naÃ¯ve.",25407031,"Specific disease- type 2 diabetes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Mexico; Other- insulin-naÃ¯ve.",Insulin detemir,An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes.,oral glucose-lowering drugs (OGLDs),SE
2013-01-14300,2013,Marti                            2013 Cost Eff Resour Alloc,3600,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru.,24004943,Healthy; Age- 0 to 18 years; Gender- Both; Country- Peru.,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV),A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.,None,NE
2013-01-14300,2013,Marti                            2013 Cost Eff Resour Alloc,4000,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Argentina.,24004943,Healthy; Age- 0 to 18 years; Gender- Both; Country- Argentina.,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV),A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.,None,NE
2013-01-14300,2013,Marti                            2013 Cost Eff Resour Alloc,4800,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Colombia.,24004943,Healthy; Age- 0 to 18 years; Gender- Both; Country- Colombia.,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV),A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.,None,NE
2013-01-14300,2013,Marti                            2013 Cost Eff Resour Alloc,5500,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Mexico.,24004943,Healthy; Age- 0 to 18 years; Gender- Both; Country- Mexico.,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV),A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.,None,NE
2013-01-14300,2013,Marti                            2013 Cost Eff Resour Alloc,8500,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Brazil.,24004943,Healthy; Age- 0 to 18 years; Gender- Both; Country- Brazil.,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV),A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.,None,NE
2013-01-14300,2013,Marti                            2013 Cost Eff Resour Alloc,Cost-Saving,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Chile.,24004943,Healthy; Age- 0 to 18 years; Gender- Both; Country- Chile.,10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV),A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.,None,SE
2012-01-10293,2012,Salinas-Escudero 2012 Salud Publica Mex,11000,Surfactant rescue treatment with bovine surfactant (BS) therapy VERSUS None IN Premature infants with respiratory distress syndrom (RDS) in Mexico,22965446,Premature infants with respiratory distress syndrom (RDS) in Mexico,Surfactant rescue treatment with bovine surfactant (BS) therapy,Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population.,None,NE
2012-01-08871,2012,D?az de Le?n-Casta?eda 2012 Clinicoecon Outcomes Res,140,Glibenclamide VERSUS Metaformin IN Adult outpatients with type 2 diabetes attending a public primary care clinic in Mexico City,22427724,Adult outpatients with type 2 diabetes attending a public primary care clinic in Mexico City,Glibenclamide,Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City.,Metaformin,NE
2012-01-08871,2012,D?az de Le?n-Casta?eda 2012 Clinicoecon Outcomes Res,770,Glibenclamide VERSUS Acarbose IN Adult outpatients with type 2 diabetes attending a public primary care clinic in Mexico City,22427724,Adult outpatients with type 2 diabetes attending a public primary care clinic in Mexico City,Glibenclamide,Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City.,Acarbose,NE
2012-01-08662,2012,Salinas-Escudero 2012 Salud Publica Mex,21000,Prophylaxis with palivizumab during 6 months of respiratory syncytial virus season (RSV) season VERSUS None IN Patients less than 29 weeks of gestational age in Mexico,22286828,Patients less than 29 weeks of gestational age in Mexico,Prophylaxis with palivizumab during 6 months of respiratory syncytial virus season (RSV) season,Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.,None,NE
1 2 3 4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
